In the statement made by Oxford University, Covid-19 It is stated that clinical trials on 300 volunteers will begin this month to evaluate whether the vaccine creates a strong immune response in those aged 6-17.
In the statement, it was noted that the first clinical studies on children will be carried out in the centers of Oxford University in the cities of London, Southampton and Bristol.
‘IT IS IMPORTANT TO CREATE THE IMMUNE RESPONSE’
Oxford University Vaccination Studies Group Principal Investigator Andrew Pollard, whose evaluations were included in the statement, stated that most children were not affected by the Covid-19 outbreak, but it is important to create an immune response to the vaccine in children and young people.
Pollard stated that these new trials will expand the understanding of the control of the Kovid-19 virus to younger age groups.
The UK Pharmaceuticals and Healthcare Products Regulatory Authority (MHRA) announced that the Covid-19 vaccine developed by the University of Oxford in cooperation with the British-Swedish pharmaceutical company AstraZenaca on December 30 was safe, and the application of the vaccine started on January 4.
The UK Vaccination and Immunization Committee, in its “vaccination priority list”, recommended that those under 16 should not be vaccinated.